Overall rank by patents
#12,812
of 49,997 tracked assignees
USPTO PatentsView assignee record - 23 granted patents across 7 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: B60N (Seats Specially Adapted FOR VEHICLES; Vehicle Passenger Accommodation NOT Otherwise Provided FOR).
The verdict
According to USPTO PatentsView, Artsana ranks #12,812 of 49,997 tracked US assignees by granted-patent volume, with 23 patents across 7 technology areas.
USPTO PatentsView assignee plate
Corpus R12812 · US Corporation #12,812 · 23 grants
GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: Aperia Technologies, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Artsana USA · this assignee
49 score
3D Lighting… · lowest
7 score
What this shows Artsana's Innovation Score is 49.0/100 (top 15% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Artsana USA, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 39.1% of grants classified under B60N (Seats Specially Adapted FOR VEHICLES; Vehicle Passenger Accommodation NOT Otherwise Provided FOR). Peak complete grant year is 2015 (5 grants) versus a trough of 1 in 2022. By volume, Artsana sits between Aperia Technologies, Inc. and Atea Pharmaceuticals, Inc..
Artsana USA, Inc. shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Aperia Technologies, Inc.
23 patents
Apstra, Inc.
23 patents
Aquestive Therapeutics, Inc.
23 patents
Armada Systems Inc.
23 patents
Aruze Gaming (Hong Kong) Limited
23 patents
AstraZeneca UK Limited
23 patents
AtScale, Inc.
23 patents
Atea Pharmaceuticals, Inc.
23 patents
Artsana USA, Inc.
23 patents
What this shows Artsana holds 23 patents at rank #12,816, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #12,816 in granted patent volume.
Other assignees with the most granted patents in Artsana's primary technology class.
Artsana's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
49 Top 15% higher than 85% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 5 | 21.7% |
| 2016 | 4 | 17.4% |
| 2017 | 4 | 17.4% |
| 2018 | 2 | 8.7% |
| 2022 | 1 | 4.3% |
| 2023 | 2 | 8.7% |
| 2024 | 2 | 8.7% |
| 2025partial year | 3 | 13.0% |
Top 7 of 7 technology areas
Overall rank by patents
#12,812
of 49,997 tracked assignees
49.0 out of 100
What to do with this data
Artsana USA, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.